Literature DB >> 17340558

The impact of impurities in synthetic peptides on the outcome of T-cell stimulation assays.

Janet W de Beukelaar1, Jan W Gratama, Peter A Sillevis Smitt, Georges M Verjans, Jaco Kraan, Theo M Luider, Peter C Burgers.   

Abstract

Protein-spanning peptide pools have proven valuable as a screening tool for detecting T-lymphocyte responses against a wide range of proteins. We have used this approach in our search for T cells reactive to the onconeural protein HuD. We found positive responses in only 3 of 127 individuals; however, these were highly unusual in that the same class I HLA alleles and peptides were involved. These T-cell responses were not confirmed when peptides re-synthesized by the same manufacturer with similar and with higher purity levels were used. Our observations indicated that these T-cell responses were not directed against the designed HuD peptides. Here, we report on (i) comparisons of the peptide batches analyzed by matrix-assisted laser desorption/ionization Fourier transform mass spectrometry (MALDI-FTMS) that did--and did not--elicit T-cell responses and (ii) a detailed analysis of the various by-products of peptides, irrespective of T-cell assay outcome. We found numerous differences between the peptide batches, such as omissions of amino acids in the primary structure of the peptides. Furthermore, some batches revealed strong interactions with calcium ions or contained sulfated peptides. Our data reveal that different batches from the same peptide may contain artefacts that influence the outcome of HLA-restricted T-cell response assays. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17340558     DOI: 10.1002/rcm.2958

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  4 in total

1.  Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening.

Authors:  R Brad Jones; Vivek M John; Diana V Hunter; Eric Martin; Shariq Mujib; Vesna Mihajlovic; Peter C Burgers; Theo M Luider; Gabor Gyenes; Neil C Sheppard; Devi Sengupta; Ravi Tandon; Feng-Yun Yue; Erika Benko; Colin Kovacs; Douglas F Nixon; Mario A Ostrowski
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

2.  Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Authors:  Jeffrey R Currier; Lynee M Galley; Holger Wenschuh; Vivian Morafo; Silvia Ratto-Kim; Clive M Gray; Leonard Maboko; Michael Hoelscher; Mary A Marovich; Josephine H Cox
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

3.  Quality evaluation of synthetic quorum sensing peptides used in R&D.

Authors:  Frederick Verbeke; Evelien Wynendaele; Sarah Braet; Matthias D'Hondt; Bart De Spiegeleer
Journal:  J Pharm Anal       Date:  2015-01-31

4.  iTRAQ-based quantitative proteomics analysis of immune thrombocytopenia patients before and after Qishunbaolier treatment.

Authors:  Yanbo Wang; Shuanglian Wang; Cuiqin Gong; Haihua Bai
Journal:  Rapid Commun Mass Spectrom       Date:  2021-02-15       Impact factor: 2.586

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.